Effect of 6-Month Vitamin D Supplementation on Plasma Matrix Gla Protein in Older Adults.

What Was Tested

This randomized controlled trial looks at Vitamin D, K2, Magnesium and Zinc.

Stored baseline and six-month follow-up blood samples were available for 131 participants (n = 65 placebo vs. n = 66 vitamin D supplementation).

The researchers measured dephosphorylated uncarboxylated matrix gla protein (MGP) (dp-ucMGP) concentrations-a marker of vitamin K deficiency.

Who Took Part

According to the abstract, 131 participants were involved.

The age groups tagged for this paper are middle-aged adults and older adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the participants nor the staff measuring them knew who was on Vitamin D, K2, Magnesium and Zinc, so expectations could not easily colour the readings.

A placebo (an inactive look-alike) gave the Vitamin D, K2, Magnesium and Zinc group a baseline to be compared against.

What Was Measured

The researchers measured dephosphorylated uncarboxylated matrix gla protein (MGP) (dp-ucMGP) concentrations-a marker of vitamin K deficiency.

The subject headings attached to it are Calcium-Binding Proteins, Cholecalciferol, Extracellular Matrix Proteins, Gene Expression Regulation and Matrix Gla Protein.

Author keywords: randomized controlled trial, vitamin D supplementation and vitamin K status.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in 131 participants.

The publication is from 2019 (Nutrients), a journal based in Switzerland.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.